PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-08-19 pm EDT
49.15 USD   +1.17%
08/19FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound -Bloomberg News
RE
08/19Pfizer to Study Repeat Paxlovid Regimen at FDA Order, Details to be Finalized This Month
MT
08/19Canada OKs Pfizer-BioNTech COVID-19 booster dose for 5 to 11 year olds
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Truveta Announces Strategic Collaboration with Pfizer to Accelerate Safety Insights in Real Time

06/22/2022 | 10:45am EDT

BELLEVUE, Wash. - Truveta announced a strategic collaboration with Pfizer to deliver new safety insights on a continuous basis, using verifiable real-world data at scale. Truveta will provide Pfizer with an unprecedented data platform for research. The data collected by Truveta are always flowing, providing the most up-to-date picture of U.S. health. Pfizer will use de-identified data from Truveta to identify, monitor, and evaluate potential signals in near-real time, informing efforts to mitigate risks and enabling further research.

Truveta is the world's first health system-led data platform with a vision of Saving Lives with Data. Truveta's 20 innovative health system members provide more than 16 percent of U.S. patient care from tens of thousands of clinical care sites across 42 states and provide ongoing governance to Truveta.

'Truveta's dataset is one of the most timely and complete datasets available in the United States, allowing Pfizer to learn directly from de-identified patient data at an unprecedented pace and scale,' said Dr. Aida Habtezion, Chief Medical Officer, and Head of Worldwide Medical and Safety, Pfizer. 'This enhances our best-in-class monitoring systems, through near real-time monitoring of safety signals in an expansive patient population. We hope to continue to find additional benefit from this growing data such as identifying and addressing health disparities.'

'Truveta's vision is Saving Lives with Data, and we are inspired to work with Pfizer to fight the devastating impacts of COVID-19 and other health conditions,' said Terry Myerson, CEO of Truveta. 'We are excited to work closely with Pfizer as we build the largest and most complete data platform for U.S. health, readily accessible through a complete analytics solution. With Truveta, researchers can be empowered with real-time data to find cures, advance patient care, and transform healthcare in the U.S. The world needs answers to medical questions faster and together, we can help.'

Learning in Real Time with Real World Data

Truveta's data platform empowers researchers to quickly monitor, query and evaluate health data from more than 50 million de-identified patient journeys, covering a broad range of diversity of the U.S. Data are updated daily and includes the full Electronic Medical Record (EMR), not just the medical bill from claims data, all fully anonymized and aggregated. This clinical data is linked across providers and with medical claims when care is provided outside Truveta's network. Every patient record is enhanced with comprehensive socio-economic data and daily mortality data for a complete picture of each patient's health journey.

Putting the Researcher at the Center with Trusted Data

In close partnership with its health system members, Truveta puts the researcher front and center in their efforts - creating the opportunity to access data for real-time learning. Truveta's learning community connects life science and health systems to innovate collaboratively, ?speed time to insights, and earn trust through transparency and ?reproducibility of research.

'As the first health system to deliver the first COVID-19 vaccine outside of a clinical trial from Pfizer-BioNTech in the U.S., we are thrilled to join together as we continue to fight this pandemic,' said Michael Dowling, President and CEO of Northwell Health. 'The collaboration between Pfizer and Truveta is an extraordinary partnership between life science and our nation's health systems all working together to ensure our communities are best protected from COVID and other health conditions.'

About Truveta

Truveta is the world's first health system-led data platform with a vision of Saving Lives with Data. Through partnerships with more than 20 innovative health system members, the Truveta platform represents the full diversity of our country across age, geography, race, ethnicity, and gender. Truveta aims to help researchers find cures faster, empower every clinician to be an expert, and help families make the most informed decision about their care. Truveta's platform is licensed for ethical medical research, not for targeting advertising to patients or physicians. Truveta is a tax paying entity. To learn more, please follow us on LinkedIn and visit truveta.com.

About Truveta's Members

Truveta's members provide more than 16 percent of U.S. patient care from tens of thousands of clinical care sites across 42 states and provide ongoing governance to Truveta. Truveta membership includes Providence, Advocate Aurora Health, Trinity Health, Tenet Healthcare, Northwell Health, AdventHealth, Baptist Health of Northeast Florida, Baylor Scott & White Health, Bon Secours Mercy Health, CommonSpirit Health, Hawaii Pacific Health, Henry Ford Health System, MedStar Health, Memorial Hermann Health System, Novant Health, Ochsner Health, Saint Luke's Health System, Sentara Healthcare, Texas Health Resources and UnityPoint Health.

Contact:

Ellie Ford

Truveta

T: 206-409-2192

E: ellief@truveta.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about PFIZER, INC.
08/19FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound -Bloomber..
RE
08/19Pfizer to Study Repeat Paxlovid Regimen at FDA Order, Details to be Finalized This Mont..
MT
08/19Canada OKs Pfizer-BioNTech COVID-19 booster dose for 5 to 11 year olds
RE
08/19Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ..
BU
08/17GSK Says No Payment Made After Zantac Plaintiff Drops Lawsuit
MT
08/17Moderna - Evidation Enables First of Its Kind Moderna Study to Track COVID Vaccine Resp..
AQ
08/17GSK shares ease after plaintiff in first Zantac lawsuit drops case
RE
08/17GSK Says First US Plaintiff to Drop Zantac Case
DJ
08/16Plaintiff in first Zantac lawsuit set for trial drops case
RE
08/16Ambrx Biopharma Names Kate Hermans Interim CEO
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,72x
Yield 2022 3,30%
Capitalization 276 B 276 B -
EV / Sales 2022 2,60x
EV / Sales 2023 3,30x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 49,15 $
Average target price 56,53 $
Spread / Average Target 15,0%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-16.77%275 847
JOHNSON & JOHNSON-1.03%438 468
ELI LILLY AND COMPANY14.66%300 939
ROCHE HOLDING AG-15.60%275 743
ABBVIE INC.4.35%249 814
NOVO NORDISK A/S2.97%233 688